Pregabalin

# Pregabalin ## Overview - **Classification**: Anticonvulsant, GABA analog (gamma-aminobutyric acid analog). - **Mechanism**: Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, modulating calcium influx and reducing excitatory neurotransmitter release. ## Primary Indications 1. **Neuropathic Pain**: Management of diabetic peripheral neuropathy and postherpetic neuralgia. 2. **Fibromyalgia**: Treatment of chronic widespread pain. 3. **Partial-Onset Seizures**: Adjunctive therapy in adults. 4. **Generalized Anxiety Disorder (GAD)**: Management of GAD in adults. ## Adult Dosing ### Standard Dosing **Neuropathic Pain (Diabetic Peripheral Neuropathy, Postherpetic Neuralgia)** - **Dose**: Start **50 mg** **TID** or **75 mg** **BID**. Titrate over 1 week to **150-300 mg/day**. - **Frequency**: **BID** or **TID** - **Route**: Oral - **Maximum Dose**: **300 mg/day** for DPN; **600 mg/day** for PHN. **Fibromyalgia** - **Dose**: Start **75 mg** **BID**. Titrate over 1 week to **150 mg** **BID**. - **Frequency**: **BID** - **Route**: Oral - **Maximum Dose**: **450 mg/day**. **Partial-Onset Seizures (Adjunctive Therapy)** - **Dose**: Start **75 mg** **BID** or **50 mg** **TID**. Titrate over 1 week to **150-300 mg** **BID**. - **Frequency**: **BID** or **TID** - **Route**: Oral - **Maximum Dose**: **600 mg/day**. **Generalized Anxiety Disorder (GAD)** - **Dose**: Start **150 mg/day** (divided **BID/TID**). Titrate up to **300 mg/day** after 1 week. - **Frequency**: **BID** or **TID** - **Route**: Oral - **Maximum Dose**: **600 mg/day**. ### Dose Adjustments - **Renal Impairment**: Dose must be reduced based on CrCl. - CrCl ≥60 mL/min: No adjustment. - CrCl 30-59 mL/min: Start **75 mg/day** (divided **BID/TID**); Max **300 mg/day**. - CrCl 15-29 mL/min: Start **25-50 mg/day** (single dose or divided **BID**); Max **150 mg/day**. - CrCl <15 mL/min: Start **25 mg/day** (single dose); Max **75 mg/day**. - Hemodialysis: Administer supplemental dose after each **4-hour** dialysis session. - **Hepatic Impairment**: No specific dose adjustment needed as pregabalin is not significantly metabolized by the liver. - **Elderly Patients**: Start at the lower end of the dosing range and titrate slowly due to potential age-related decline in renal function and increased sensitivity to adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended due to lack of safety and efficacy data. - **Special Notes**: Avoid use in this age group. ### Infants (1-12 months) - **Dose**: Not recommended due to lack of safety and efficacy data. - **Special Notes**: Avoid use in this age group. ### Children (1-12 years) **Partial-Onset Seizures (Adjunctive Therapy)** (Off-label/Limited data in some regions) - **Dose**: Start **2.5 mg/kg/day** (divided **BID** or **TID**). Titrate weekly by **2.5-5 mg/kg/day** increments. - **Frequency**: **BID** or **TID** - **Maximum**: **10 mg/kg/day** or **600 mg/day**, whichever is less. - **Formulation**: Oral solution (if available) or capsule contents mixed with food. - **Special Notes**: Closely monitor for sedation and withdrawal symptoms upon discontinuation. ### Adolescents (13-18 years) **Partial-Onset Seizures (Adjunctive Therapy)** (Off-label/Limited data in some regions) - **Dose**: Generally follow adult dosing, starting with **75 mg** **BID** or **50 mg** **TID**. - **Frequency**: **BID** or **TID** - **Maximum**: **600 mg/day**. - **Special Notes**: Initiate with lower doses and titrate slowly. Monitor for dose-related adverse effects. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to pregabalin or any component of the formulation. - **Relative**: History of angioedema (increased risk when combined with ACE inhibitors). ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, somnolence (sedation), dry mouth, peripheral edema, blurred vision, weight gain. - **Common (1-10%)**: Headache, fatigue, ataxia, confusion, euphoria, tremor, constipation, increased appetite, erectile dysfunction. - **Serious but Rare**: Angioedema, hypersensitivity reactions, suicidal ideation, rhabdomyolysis, respiratory depression (especially with CNS depressants). ### Key Drug Interactions - **CNS Depressants (Opioids, Benzodiazepines, Alcohol)**: Increased risk of sedation, respiratory depression, and coma. Use with extreme caution; dose reduction of one or both agents may be necessary. - **ACE Inhibitors**: Increased risk of angioedema when co-administered. Monitor for signs of facial or laryngeal swelling. - **Thiazolidinediones (e.g., Pioglitazone)**: Increased risk of peripheral edema and weight gain. Monitor for fluid retention, especially in patients with cardiac disease. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline renal function (CrCl). - **During Treatment**: - Monitor for therapeutic response and adverse effects (dizziness, somnolence, edema). - Observe for changes in mood or behavior, including suicidal thoughts, especially at initiation or with dose changes. - Periodically reassess renal function, particularly in elderly patients or those with worsening renal impairment. - **Clinical Signs**: Watch for peripheral or facial swelling, difficulty breathing, significant behavioral changes. ## Clinical Pearls - 💡 **Gradual Titration**: Always titrate pregabalin dose up slowly over at least 1 week to minimize dizziness and somnolence. - 💡 **Abrupt Discontinuation**: Avoid abrupt discontinuation; taper dose over at least 1 week to prevent withdrawal symptoms (e.g., insomnia, nausea, headache, anxiety, seizures). - 💡 **Food Effect**: Can be taken with or without food. - 💡 **Driving/Operating Machinery**: Counsel patients about potential for dizziness, somnolence, and blurred vision; advise against driving or operating heavy machinery until effects are known. - 💡 **Controlled Substance**: Pregabalin is a Schedule V controlled substance; potential for abuse and dependence exists. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.